Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Rheumatology and Therapy is Scopus-indexed (Q1, CiteScore 5.9), WoS SCIE, DOAJ. Published by Adis.
Checked against the index lists dated .
ISSN 2198-6576Verify ISSN ↗2198-6584Verify ISSN ↗
Publisher: Adis
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Rheumatology | 16 / 77 | 79th | Q1 |
| Immunology and Allergy | 89 / 234 | 62nd | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2014–present, best quartile Q1, CiteScore 5.9.
Rheumatology and Therapy is Q1 in Rheumatology (rank 16 of 77) and Q2 in Immunology and Allergy (rank 89 of 234), by CiteScore 2025.
Rheumatology and Therapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.9, which places it in quartile Q1 at the 79th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.991, quartile Q2, with an H-index of 47.
The publisher lists an article processing charge of about US$7,400 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Rheumatology and Therapy is published by Adis. Its print ISSN is 2198-6576 and its online ISSN is 2198-6584.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Rheumatology and Therapy has an h-index of 54 and a 2-year mean of 3.44 citations per paper (OpenAlex). Its Scopus CiteScore is 5.9, quartile Q1. On 2-year citations it ranks #14 of 74 Scopus journals in Rheumatology.
Rheumatology and Therapy published 84 papers in 2025; its busiest recent year was 2021 with 142. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from United States (23.6%), China (10.7%) and Italy (9.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.